(NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...

(CRBP), a biopharmaceutical company, today, announced that the FDA has granted Fast Track Designation to CRB-701 in treating relapsed or refractory metastatic cervical cancer patients. The FDA's ...

(NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that the U.S. Food and Drug ...

CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE as the ...

BISMARCK, ND (KXNET) — The F5 Project, a member of the North Dakota Association of Nonprofit Organizations (NDANO), is transforming lives and redefining second chances. Founded in 2016 by Adam Martin, ...

TERN-701 is an investigational, oral, potent, small molecule allosteric BCR-ABL inhibitor being developed for patients with CML. CARDINAL is a global, multicenter, open-label, two-part Phase 1 ...

TERN-701 showed promising early results, with significant molecular responses and a strong safety profile in heavily pre-treated patients with chronic myeloid leukemia. Encouraging early data from the ...

Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for ... Terns Pharmaceuticals, Inc. - (GLOBE NEWSWIRE) Dec 3, 2024 ...